Abstract
S100P is an EF-hand calcium-binding protein that was originally identified in placenta and subsequently associated with cancer. It is a member of S100 family of proteins that function as extracellular and/or intracellular regulators of diverse cellular processes and participate in various human pathologies. S100P expression was detected in a spectrum of human tumor cell lines and tissues derived from breast, prostate, pancreas, lung and colon, where it was connected with malignant phenotype, hormone independence and resistance to chemotherapy. Overexpression of S100P was shown to promote tumorigenesis and metastasis in diverse cancer models. Functional studies of S100P indicate that its biological activities are exerted through extracellular signaling via RAGE receptor, resulting in increased proliferation and survival, or through intracellular interaction with ezrin, leading to increased cell migration and metastasis. Molecular mechanisms regulating expression of S100P in cancer cells are just emerging. Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression. Functional analysis of S100P promoter identified SMAD, STAT/CREB and SP/KLF binding sites as key regulatory elements participating in transcriptional activation of S100P gene in cancer cells. Moreover, the most recent data reveal that expression of S100P is up-regulated by activation of glucocorticoid receptor suggesting that S100P could play a role in therapy resistance mediated by glucocorticoids in solid tumors. Elucidation of S100P regulation is an important step towards understanding biological significance of its tissue distribution and proposing strategies for targeted S100P modulation.
Similar content being viewed by others
References
Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM (2000) Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 60:6134–6141
Arumugam T, Simeone DM, Schmidt AM, Logsdon CD (2004) S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 279:5059–5065
Arumugam T, Simeone DM, Van Golen K, Logsdon CD (2005) S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 11:5356–5364
Austermann J, Nazmi AR, Muller-Tidow C, Gerke V (2008) Characterization of the Ca2+-regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem 283:29331–29340
Averboukh L, Liang P, Kantoff PW, Pardee AB (1996) Regulation of S100P expression by androgen. Prostate 29:350–355
Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A (2007) S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 43:1935–1943
Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S (2008) Functional evidence implicating S100P in prostate cancer progression. Int J Cancer 123:330–339
Becker T, Gerke V, Kube E, Weber K (1992) S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 207:541–547
Bertram J, Palfner K, Hiddemann W, Kneba M (1998) Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 9:311–317
Black AR, Black JD, Azizkhan-Clifford J (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188:143–160
Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR (2005) Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 97:328–341
Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, Gerke V, Hotfilder M, Vormoor J, Berdel WE, Serve H, Muller-Tidow C (2008) Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. Cancer Res 68:1896–1904
Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP, Lemoine NR (2003) Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201:63–74
Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F (2008) Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol 129:81–88
Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zanker KS, Metzger R, Schneider PM, Gerke V, Thomas M, Berdel WE, Serve H, Muller-Tidow C (2004) S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64:5564–5569
Donato R (2003) Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60:540–551
Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, Brentnall TA, Luttges J, Kloppel G, Lemoine NR (2005) Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol 166:81–92
Filipek A, Jastrzebska B, Nowotny M, Kuznicki J (2002) CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem 277:28848–28852
Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, Huang EH (2007) RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 50:1230–1240
Fukushima N, Sato N, Prasad N, Leach SD, Hruban RH, Goggins M (2004) Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 23:9042–9051
Gibadulinova A, Barathova M, Kopacek J, Hulikova A, Pastorekova S, Kettmann R, Pastorek J (2005) Expression of S100P protein correlates with and contributes to the tumorigenic capacity of HeLa cervical carcinoma cells. Oncol Rep 14:575–582
Gibadulinova A, Oveckova I, Parkkila S, Pastorekova S, Pastorek J (2008) Key promoter elements involved in transcriptional activation of the cancer-related gene coding for S100P calcium-binding protein. Oncol Rep 20:391–396
Gribenko AV, Hopper JE, Makhatadze GI (2001) Molecular characterization and tissue distribution of a novel member of the S100 family of EF-hand proteins. Biochemistry 40:15538–15548
Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X, Russo J (2000) S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol 16:231–240
Hamada S, Satoh K, Hirota M, Fujibuchi W, Kanno A, Umino J, Ito H, Satoh A, Kikuta K, Kume K, Masamune A, Shimosegawa T (2009) Expression of the calcium-binding protein S100P is regulated by bone morphogenetic protein in pancreatic duct epithelial cell lines. Cancer Sci 100:103–110
Hammacher A, Thompson EW, Williams ED (2005) Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 37:442–450
He Z, Gao J, Wang Q, Liu M, Li Y, Li X, Tang H, Zheng J (2008) S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3. Oncol Rep 20:325–332
Heizmann CW, Cox JA (1998) New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Biometals 11:383–397
Heizmann CW, Fritz G, Schafer BW (2002) S100 proteins: structure, functions and pathology. Front Biosci 7:d1356–d1368
Hsieh HL, Schafer BW, Sasaki N, Heizmann CW (2003) Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 307:375–381
Hsieh HL, Schafer BW, Weigle B, Heizmann CW (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun 316:949–959
Jakubickova L, Barathova M, Pastorekova S, Pastorek J, Gibadulinova A (2005) Expression of S100P gene in cervical carcinoma cells is independent of E7 human papillomavirus oncogene. Acta Virol 49:133–137
Jiang F, Shults K, Flye L, Hashimoto Y, Van Der Meer R, Xie J, Kravtsov V, Price J, Head DR, Briggs RC (2005) S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents. Leuk Res 29:1181–1190
Kassel O, Herrlich P (2007) Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol 275:13–29
Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP (2009) Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun 381:671–675
Koltzscher M, Gerke V (2000) Identification of hydrophobic amino acid residues involved in the formation of S100P homodimers in vivo. Biochemistry 39:9533–9539
Koltzscher M, Neumann C, Konig S, Gerke V (2003) Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 14:2372–2384
Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649–2657
Mandinova A, Atar D, Schafer BW, Spiess M, Aebi U, Heizmann CW (1998) Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium. J Cell Sci 111(Pt 14):2043–2054
Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111–1122
Marenholz I, Lovering RC, Heizmann CW (2006) An update of the S100 nomenclature. Biochim Biophys Acta 1763:1282–1283
Matsuzawa SI, Reed JC (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7:915–926
Mattern J, Buchler MW, Herr I (2007) Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther 6:1345–1354
McCabe MT, Brandes JC, Vertino PM (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15:3927–3937
Missiaglia E, Blaveri E, Terris B, Wang YH, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Lemoine NR (2004) Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer 112:100–112
Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP (2001) Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20:6718–6723
Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, Kallioniemi OP (2002) Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 62:1256–1260
Mueller A, Bachi T, Hochli M, Schafer BW, Heizmann CW (1999) Subcellular distribution of S100 proteins in tumor cells and their relocation in response to calcium activation. Histochem Cell Biol 111:453–459
Namba T, Homan T, Nishimura T, Mima S, Hoshino T, Mizushima T (2009) Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects. J Biol Chem 284:4158–4167
Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M (2006) S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 12:5411–5416
Parkkila S, Pan PW, Ward A, Gibadulinova A, Oveckova I, Pastorekova S, Pastorek J, Martinez AR, Helin HO, Isola J (2008) The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol 8:2
Rehbein G, Simm A, Hofmann HS, Silber RE, Bartling B (2008) Molecular regulation of S100P in human lung adenocarcinomas. Int J Mol Med 22:69–77
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396:201–214
Sato N, Hitomi J (2002) S100P expression in human esophageal epithelial cells: human esophageal epithelial cells sequentially produce different S100 proteins in the process of differentiation. Anat Rec 267:60–69
Sato N, Fukushima N, Matsubayashi H, Goggins M (2004) Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 23:1531–1538
Schoneveld OJ, Gaemers IC, Lamers WH (2004) Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 1680:114–128
Schor AP, Carvalho FM, Kemp C, Silva ID, Russo J (2006) S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol Rep 15:3–6
Song J, Shih IeM, Chan DW, Zhang Z (2009): Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia 11:605–614, 1 p following 614
Surowiak P, Maciejczyk A, Materna V, Drag-Zalesinska M, Wojnar A, Pudelko M, Kedzia W, Spaczynski M, Dietel M, Zabel M, Lage H (2007) Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology 51:125–128
Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR (2002) Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160:1745–1754
Tutar Y (2006) Dimerization and ion binding properties of S100P protein. Protein Pept Lett 13:301–306
Wang G, Zhang S, Fernig DG, Spiller D, Martin-Fernandez M, Zhang H, Ding Y, Rao Z, Rudland PS, Barraclough R (2004) Heterodimeric interaction and interfaces of S100A1 and S100P. Biochem J 382:375–383
Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS (2006) Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 66:1199–1207
Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR (2007) Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 26:6560–6565
Wang Q, He Z, Gao J, Hu S, Huang M, Liu M, Zheng J, Tang H (2008) S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro. Cancer Lett 272:277–284
Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, Crnogorac-Jurcevic T (2007) The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res 67:8633–8642
Zhang H, Wang Z, Ding Y, Wang G, Wang X, Gao F, Tang H, Barraclough R, Rudland PS, Rao Z (2002) Purification, crystallization and preliminary X-ray diffraction studies of a Ca2+-binding protein, human S100P. Acta Crystallogr D Biol Crystallogr 58:694–696
Zhang H, Wang G, Ding Y, Wang Z, Barraclough R, Rudland PS, Fernig DG, Rao Z (2003) The crystal structure at 2A resolution of the Ca2+-binding protein S100P. J Mol Biol 325:785–794
Acknowledgments
The research of the authors is supported by the Slovak Scientific Grant Agency (VEGA 2/0143/08).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gibadulinova, A., Tothova, V., Pastorek, J. et al. Transcriptional regulation and functional implication of S100P in cancer. Amino Acids 41, 885–892 (2011). https://doi.org/10.1007/s00726-010-0495-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-010-0495-5